Shots:
- CSPC & AstraZeneca have entered into a strategic collaboration, option & license agreement to leverage CSPC’s siRNA discovery & extrahepatic targeted delivery platforms to develop novel small nucleic acid therapeutics
- CSPC & AstraZeneca will jointly discover & develop preclinical candidates for two renal disease targets, with AstraZeneca holding options for global/ex-China rights to each program (as applicable), while CSPC retains China rights to one preclinical asset
- As per the deal, CSPC will receive $30M upfront & ~$540M in development milestones & ~$1.2B in sales milestones, plus potential single-digit royalties based on the annual net sales of the products
Ref: CSPC | Image: CSPC & AstraZeneca | Press Release
Related News: CSPC Pharmaceutical and AstraZeneca Seal ~$18.5B Long-Acting Peptide Deal for Obesity
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
